Agenus Partners with Zydus Lifesciences to Enhance Biologics Manufacturing Capabilities

Agenus Partners with Zydus Lifesciences to Strengthen Biologics Manufacturing Capabilities

Agenus Inc. solidifies its strategic positioning in the biopharmaceutical sector through a significant partnership with Zydus Lifesciences Limited. This collaboration, established via a successful Asset Purchase Agreement, Share Purchase Agreement, and exclusive Licensing Agreement, aims to enhance the United States' domestic supply chain for advanced therapies. This development comes after Zydus received all necessary regulatory approvals, including clearance from the Committee on Foreign Investment in the United States (CFIUS), paving the way for the creation of a new subsidiary, Zylidac Bio LLC. This subsidiary will focus on high-quality biological manufacturing services, catering to biopharmaceutical companies globally.

Dr. Garo Armen, Chairman and CEO of Agenus, emphasizes that this partnership allows for the effective monetization of Agenus' manufacturing assets. By combining Agenus' innovative immunotherapy pipeline with Zydus' operational scale, the collaboration strengthens the existing U.S. biologics capacity for products such as botensilimab and balstilimab. This strategic alignment not only enhances the capabilities of Zydus but also allows Agenus to leverage Zydus' resources to scale its operations and accelerate the development of its therapeutic offerings.

The timing of this partnership is particularly significant, given the recent enactment of the BIOSECURE Act, which restricts U.S. government agencies from engaging with specific biotechnology firms. This legislation positions Zydus as a secure and compliant partner for global biopharmaceutical companies, ensuring that the manufacturing process aligns with regulatory standards. Earlier in 2025, Zydus had already initiated its Global BioCDMO Services following the acquisition of Agenus' facilities in Emeryville and Berkeley, reinforcing its commitment to becoming a leading provider for the production of critical drugs in the evolving biopharmaceutical landscape.

In addition to the immediate benefits of this partnership, the collaboration highlights a growing trend in the biopharmaceutical industry towards integrating manufacturing capabilities with innovative drug development. By fostering such partnerships, companies can optimize their resources and ensure that they remain competitive in an increasingly complex market. This strategic move not only positions Agenus for future growth but also reflects the ongoing evolution of the biologics sector as it adapts to changing regulatory environments.

Agenus and Zydus Lifesciences' alliance signifies a forward-thinking approach to addressing the challenges in biopharmaceutical manufacturing. As the industry continues to evolve, such collaborations may set new standards for operational efficiency and compliance in drug development.